| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3995245 | The Lancet Oncology | 2007 | 7 Pages |
Abstract
SummaryMany attempts have been made to derive genetic signatures for progressive prostate cancer for both prognostic and therapeutic purposes. These investigations have resulted in the discovery of many pathways, but the signatures exhibit heterogeneity and restricted reproducibility. A thorough and disciplined analysis of genes with androgen-response elements that are expressed in progressive, castration-resistant prostate cancer is an integral step towards the development of new therapeutic or diagnostic targets. We discuss the effects of bona-fide downstream targets of the androgen receptor on cellular proliferation, evasion of apoptosis, and angiogenesis, and consider the clinical potential of these targets.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Andrew C Hsieh, Eric J Small, Charles J Ryan,